Clinical pilot study on high-dose intraarterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma.
BACKGROUND
We recently developed a novel system of direct hemoperfusion under hepatic venous isolation in an attempt to achieve high-dose intraarterial chemotherapy for patients with malignant liver tumors. We report here the results of treatment of these patients with advanced hepatocellular carcinoma.


METHODS
Adriamycin (100 to 150 mg/m2) was administered into the hepatic artery of 15 patients, under conditions of extracorporeal drug elimination by direct hemoperfusion under hepatic venous isolation. Hepatic venous isolation was accomplished mainly by the double-balloon technique with an occlusion catheter and a balloon catheter. The isolated hepatic venous blood was filtered by direct hemoperfusion and pumped to the left axillary vein.


RESULTS
During 5 minutes of adriamycin infusion, the mean drug extraction ratios of the direct hemoperfusion filters were 91% +/- 9% (mean +/- SD). The amount of drug removed by the system was 26.4% +/- 16.0% of the amount of drug administered. Two patients died, one of necrotizing pancreatitis and the other of hepatic arterial thrombosis. Both deaths were related directly to the hepatic arterial catheter. Other side effects included hemolysis related to the system of hemoperfusion (87%), chemical hepatitis (80%), leukopenia less than 3000/mm3 (67%), alopecia (33%), and nausea and vomiting (20%). Nine (64%) of 14 evaluable patients had objective tumor responses, with a median duration of response of 6.2 months.


CONCLUSIONS
This approach offers an effective therapeutic option for patients with advanced hepatocellular carcinoma.
Ku
Y
Y
First Department of Surgery, Kobe University School of Medicine, Japan.
Fukumoto
T
T
Iwasaki
T
T
Tominaga
M
M
Samizo
M
M
Nishida
T
T
Kuroda
Y
Y
Hirota
S
S
Sako
M
M
Obara
H
H
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002404:Catheterization / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000506:poisoning / Q000627:therapeutic use; D005260:Female; D006406:Hematoma / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006439:Hemodynamics; D006464:Hemoperfusion / Q000009:adverse effects; D006503:Hepatic Veins; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016019:Survival Analysis
D000970:Antineoplastic Agents; D004317:Doxorubicin